The Epoch Times
The Epoch Times
Focus

lilly

Companies
Companies
|
Reuters

Eli Lilly to Invest Additional $1.6 Billion in 2 New Plants

Apr 17, 2023
|
Reuters
FacebookXTruthGettrLinkedInTelegramEmail
Eli Lilly to Invest Additional $1.6 Billion in 2 New Plants
Apr 17
|
FacebookXTruthGettrLinkedInTelegramEmail
Companies
Companies
|
Reuters

Eli Lilly to Make COVID-19 Antibody Drug Commercially Available From August

Aug 05, 2022
|
Reuters
FacebookXTruthGettrLinkedInTelegramEmail
Eli Lilly to Make COVID-19 Antibody Drug Commercially Available From August
Aug 05
|
FacebookXTruthGettrLinkedInTelegramEmail
Home
Home
|
Jeff Rugg

Ponds and Waterlilies

Jun 16, 2022
|
Jeff Rugg
FacebookXTruthGettrLinkedInTelegramEmail
Ponds and Waterlilies
Jun 16
|
FacebookXTruthGettrLinkedInTelegramEmail
US News
US News
|
Reuters

Eli Lilly Backs US Proposal on Drug Rebates to Lower Costs

Feb 07, 2019
|
Reuters
FacebookXTruthGettrLinkedInTelegramEmail
Eli Lilly Backs US Proposal on Drug Rebates to Lower Costs
Feb 07
|
FacebookXTruthGettrLinkedInTelegramEmail
Companies
Companies
|
Reuters

Eli Lilly to Invest Additional $1.6 Billion in 2 New Plants

Apr 17, 2023
|
Reuters
FacebookXTruthGettrLinkedInTelegramEmail
Eli Lilly to Invest Additional $1.6 Billion in 2 New Plants
Apr 17
|
FacebookXTruthGettrLinkedInTelegramEmail
Companies
Companies
|
Reuters

Eli Lilly to Make COVID-19 Antibody Drug Commercially Available From August

Aug 05, 2022
|
Reuters
FacebookXTruthGettrLinkedInTelegramEmail
Eli Lilly to Make COVID-19 Antibody Drug Commercially Available From August
Aug 05
|
FacebookXTruthGettrLinkedInTelegramEmail
Home
Home
|
Jeff Rugg

Ponds and Waterlilies

Jun 16, 2022
|
Jeff Rugg
FacebookXTruthGettrLinkedInTelegramEmail
Ponds and Waterlilies
Jun 16
|
FacebookXTruthGettrLinkedInTelegramEmail
US News
US News
|
Reuters

Eli Lilly Backs US Proposal on Drug Rebates to Lower Costs

Feb 07, 2019
|
Reuters
FacebookXTruthGettrLinkedInTelegramEmail
Eli Lilly Backs US Proposal on Drug Rebates to Lower Costs
Feb 07
|
FacebookXTruthGettrLinkedInTelegramEmail
home-iconepochtv-iconhealth-iconbright-iconepochfun-icon
The Epoch Times
To ensure we reach the high standards of reliability and neutrality that you expect from us, we are engaging with Ad Fontes Media to analyze our content. If you find an article you think falls short of the standard, please submit the link through this form.
Copyright © 2000 - 2025 The Epoch Times Association Inc. All Rights Reserved.